Cargando…

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment

Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research on how to improve the therapeutic efficacy is warranted. A potential way o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruigrok, Eline A. M., Verkaik, Nicole S., de Blois, Erik, de Ridder, Corrina, Stuurman, Debra, Roobol, Stefan J., Van Gent, Dik C., de Jong, Marion, Van Weerden, Wytske M., Nonnekens, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316488/ https://www.ncbi.nlm.nih.gov/pubmed/35887398 http://dx.doi.org/10.3390/ijms23148037

Ejemplares similares

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
por: Reuvers, Thom G.A., et al.
Publicado: (2023)

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
por: Feijtel, Danny, et al.
Publicado: (2023)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
por: Koustoulidou, Sofia, et al.
Publicado: (2022)

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
por: Murce, Erika, et al.
Publicado: (2023)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
por: Zhang, Wenhao, et al.
Publicado: (2018)

Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model()
por: Mout, Lisanne, et al.
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
por: Murce, Erika, et al.
Publicado: (2023)

Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair
por: Zhang, Wenhao, et al.
Publicado: (2019)

Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids
por: Van Hemelryk, Annelies, et al.
Publicado: (2023)

Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer
por: Murce, Erika, et al.
Publicado: (2023)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models
por: van de Merbel, Arjanneke F., et al.
Publicado: (2021)

Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

[(212)Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
por: Chapeau, Dylan, et al.
Publicado: (2023)

Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation
por: Gasi, Delila, et al.
Publicado: (2011)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
por: Murce, Erika, et al.
Publicado: (2023)

In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
por: Stroet, Marcus C. M., et al.
Publicado: (2020)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture
por: Chakrabarty, Sanjiban, et al.
Publicado: (2022)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
por: Ladan, Marjolijn M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ir92pk1fv973shpteal02gvsqa